Nektar Therapeutics (NKTR) EBT (2010 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly EBT of -$43.1 million in Q1 2026, down 24.17% quarter-over-quarter from -$34.7 million in Q4 2025, and up 7.07% on a YoY basis from -$40.2 million in Q1 2025.
Nektar Therapeutics (NKTR) EBT (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBT history runs 17 years deep, the most recent figure standing at -$43.1 million for Q1 2026.
- In Q1 2026, EBT rose 7.07% year-over-year to -$43.1 million; the TTM figure through Mar 2026 stood at -$152.2 million (down 18.24% YoY), while the FY2025 annual figure was -$155.5 million, down 30.44% from the prior year.
- EBT was -$43.1 million for Q1 2026 at Nektar Therapeutics, down from -$34.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $7.0 million in Q4 2024 to a low of -$159.0 million in Q2 2022.
- Historically, EBT has averaged -$56.3 million across 5 years, with a median of -$45.9 million in 2023.
- The sharpest annual moves came in 2024 and 2025: EBT jumped 117.14% in 2024, then plunged 595.6% in 2025.
- A 5-year view of EBT shows it stood at -$56.5 million in 2022, then climbed by 27.76% to -$40.8 million in 2023, then surged by 117.14% to $7.0 million in 2024, then slumped by 595.6% to -$34.7 million in 2025, then fell by 24.17% to -$43.1 million in 2026.
- The last three EBT figures came in at -$43.1 million (Q1 2026), -$34.7 million (Q4 2025), and -$35.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | -43.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.09 Mn |
| Dec 31, 2025 | -34.70 Mn |
| Sep 30, 2025 | -35.02 Mn |
| Jun 30, 2025 | -39.40 Mn |
| Mar 31, 2025 | -46.37 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Sep 30, 2024 | -37.05 Mn |
| Jun 30, 2024 | -52.32 Mn |
| Mar 31, 2024 | -36.84 Mn |
| Dec 31, 2023 | -40.85 Mn |
| Sep 30, 2023 | -45.90 Mn |
| Jun 30, 2023 | -51.17 Mn |
| Mar 31, 2023 | -137.08 Mn |
| Dec 31, 2022 | -56.54 Mn |
| Sep 30, 2022 | -59.20 Mn |
| Jun 30, 2022 | -158.97 Mn |
| Mar 31, 2022 | -90.27 Mn |
| Dec 31, 2021 | -145.65 Mn |
| Sep 30, 2021 | -129.59 Mn |
| Jun 30, 2021 | -125.16 Mn |